Related Experiment Video
Updated: Jun 4, 2025
Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
Published on: February 20, 2019
Innovative mRNA Vaccine Approaches in Targeting Atherosclerosis: A New Era in Cardiovascular Therapy
Rahul Kumar1, Gowri Krishnaperumal2, Chitra Vellapandian1
1Pharmacy/Pharmacology, SRM College of Pharmacy, SRM Institute of Science and Technology (SRMIST), Chengalpattu, IND.
Abstract:
Atherosclerosis, a major cause of cardiovascular disease (CVD), involves plaque buildup in arteries driven by inflammation, endothelial dysfunction, and lipid metabolism disturbances. Current therapies aim to reduce cholesterol through statins and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, prevent blood clots with antiplatelet drugs like aspirin, and control inflammation, alongside lifestyle modifications. However, these approaches often fall short due to patient non-compliance and residual risks. This review explores emerging mRNA vaccine strategies targeting the complex mechanisms of atherosclerosis. These vaccines could produce therapeutic proteins to modulate inflammation by encoding sequences that inhibit pro-inflammatory cytokines such as interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α), stabilizing plaques. Key targets include interleukin-10 (IL-10) for plaque stability, PCSK9 for cholesterol regulation, and vascular endothelial growth factor (VEGF) for endothelial repair. Addressing these unmet needs, mRNA-based approaches offer the potential for more effective and personalized treatments for atherosclerosis. However, challenges remain, including difficulty replicating human atherosclerosis in preclinical models, regulatory concerns about long-term safety, and ensuring accessibility in low-resource settings. In addition, large and diverse clinical trials are needed to confirm the efficacy of these vaccines in reducing cardiovascular events.
Insights
Emerging mRNA vaccines show promise for treating atherosclerosis by modulating inflammation and cholesterol. These novel therapies aim to improve plaque stability and endothelial repair, addressing limitations of current cardiovascular disease treatments.
Area of Science:
- Cardiovascular Science
- Immunology
- Biotechnology
Background:
- Atherosclerosis, a primary driver of cardiovascular disease (CVD), results from arterial plaque buildup due to inflammation, endothelial dysfunction, and lipid metabolism issues.
- Current CVD treatments like statins, PCSK9 inhibitors, and antiplatelet drugs have limitations, including patient non-compliance and residual cardiovascular risk.
- Existing therapies often fail to fully address the complex inflammatory and metabolic pathways underlying atherosclerosis progression.
Purpose of the Study:
- To explore the potential of messenger RNA (mRNA) vaccine strategies for therapeutic intervention in atherosclerosis.
- To identify key molecular targets for mRNA vaccines, including pro-inflammatory cytokines (IL-1β, IL-6, TNF-α), IL-10, PCSK9, and VEGF.
- To evaluate the feasibility of mRNA technology in developing novel treatments for atherosclerosis, aiming for improved efficacy and personalization.
Main Methods:
- Review of emerging mRNA vaccine strategies and their potential applications in atherosclerosis.
- Analysis of therapeutic protein targets for mRNA vaccine design, focusing on immunomodulation and lipid metabolism.
- Exploration of mechanisms by which mRNA vaccines could encode therapeutic proteins to inhibit inflammatory cytokines and promote plaque stability.
Main Results:
- mRNA vaccines can be designed to produce therapeutic proteins that modulate inflammation by inhibiting key pro-inflammatory cytokines (IL-1β, IL-6, TNF-α).
- Potential targets for mRNA vaccines include IL-10 for plaque stabilization, PCSK9 for cholesterol reduction, and VEGF for endothelial repair.
- mRNA technology offers a platform for personalized treatments targeting specific atherosclerotic pathways.
Conclusions:
- mRNA vaccines represent a promising, novel therapeutic avenue for atherosclerosis, potentially overcoming limitations of current treatments.
- Further research and large, diverse clinical trials are essential to validate the efficacy and long-term safety of mRNA vaccines in reducing cardiovascular events.
- Challenges including preclinical model limitations, regulatory hurdles, and accessibility in low-resource settings must be addressed for widespread adoption.
Related Concept Videos
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:29Microorganisms in Medicine and Therapeutics